FGFR4 and metabolic dysfunction-associated steatohepatitis: In NASH, the levels of serum FGF19, fibroblast growth factor receptor 4 (FGFR4), and bile acids are significantly increased, and results in impaired FXR and FGFR4-mediated signaling [317,318].